{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:05:07Z","timestamp":1789909507119,"version":"4.0.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p> Our objective was to determine the efficacy and safety of imiquimod 5% cream in the treatment of external genital\/perianal warts in an open-label Phase IIIB trial. Patients applied imiquimod 5% cream 3 times per week, for up to 16 weeks. Those who cleared their warts were monitored during a 6-month follow-up period. If their warts recurred, or new warts developed during this time, patients could be re-treated for up to 16 additional weeks. Patients who experienced partial clearance during the initial treatment period entered an extended treatment period of up to an additional 16 weeks. A total of 943 patients from 114 clinic sites in 20 countries participated in this study. Complete clinical clearance was observed in 451\/943 (47.8%) patients (intent-to-treat (ITT) analysis) during the initial treatment period, with clearance in an additional 52 (5.5%) patients during the extended treatment period beyond 16 weeks. The overall clearance rate for the combined treatment periods was 53.3%. In a treatment failure analysis, the overall clearance rate was 65.5%; a greater proportion of female patients (75.5%) experienced complete clearance than male patients (56.9%). Low recurrence rates, of 8.8% and 23.0%, were observed at the end of the 3- and 6-month follow-up periods, respectively. The sustained clearance rates (patients who cleared during treatment and remained clear at the end of the follow-up period) after 3 and 6 months were 41.6% and 33.0% (ITT analysis), respectively. Local erythema occurred in 67% of patients. In the majority of patients local skin reactions were of mild to moderate severity. In conclusion, imiquimod 5% cream is an effective self-applied treatment for external genital\/perianal warts when applied for up to 16 weeks and is well tolerated for up to 32 weeks. <\/jats:p>","DOI":"10.1258\/0956462011924218","type":"journal-article","created":{"date-parts":[[2002,10,16]],"date-time":"2002-10-16T09:48:30Z","timestamp":1034761710000},"page":"722-729","source":"Crossref","is-referenced-by-count":73,"title":["Imiquimod 5% Cream is a Safe and Effective Self-Applied Treatment for Anogenital Warts \u2014 Results of an Open-Label, Multicentre Phase IIIB Trial"],"prefix":"10.1177","volume":"12","author":[{"given":"S M","family":"Garland","sequence":"first","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Royal Women's and Royal Children's Hospitals, Melbourne and Melbourne Sexual Health Centre, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Sellors","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Wikstrom","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology, Karolinska Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Aranda","sequence":"additional","affiliation":[{"name":"Montes Urales No 800, Instituto Nacional de Verinatolog\u00eda, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Aractingi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tenon Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R D","family":"Maw","sequence":"additional","affiliation":[{"name":"Department of Genito-Urinary Medicine, Royal Victoria Hospital, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2001,11,1]]},"reference":[{"key":"bibr1-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199904001-00002"},{"key":"bibr2-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1984.01650400058013"},{"key":"bibr3-0956462011924218","first-page":"329","volume":"70","author":"Lyttle P.H.","year":"1994","journal-title":"Genitourin Med"},{"key":"bibr4-0956462011924218","doi-asserted-by":"publisher","DOI":"10.3109\/00016349609047103"},{"key":"bibr5-0956462011924218","first-page":"365","volume":"73","author":"Simms I.","year":"1997","journal-title":"Genitourin Med"},{"key":"bibr6-0956462011924218","first-page":"S1","volume":"8","author":"Hughes G.I.","year":"1998","journal-title":"Commun Dis Rep CDR Suppl"},{"key":"bibr7-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00177-0"},{"key":"bibr8-0956462011924218","first-page":"503","volume":"163","author":"Sellors J.W.","year":"2000","journal-title":"CMAJ"},{"key":"bibr9-0956462011924218","first-page":"109","volume":"42","author":"Garland S.M.","year":"1999","journal-title":"Modern Med Aust"},{"key":"bibr10-0956462011924218","first-page":"RR1","volume":"47","author":"CDC.","year":"1997","journal-title":"MMWR"},{"key":"bibr11-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1136\/sti.76.3.162"},{"key":"bibr12-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(88)90032-0"},{"key":"bibr13-0956462011924218","first-page":"3528","volume":"52","author":"Sidky Y.A.","year":"1992","journal-title":"Cancer Res"},{"key":"bibr14-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1086\/517472"},{"key":"bibr15-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/102.6.768"},{"key":"bibr16-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.25"},{"key":"bibr17-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1258\/0956462011923723"},{"key":"bibr18-0956462011924218","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)87244-6"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462011924218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1258\/0956462011924218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T01:25:09Z","timestamp":1740965109000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1258\/0956462011924218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1258\/0956462011924218"],"URL":"https:\/\/doi.org\/10.1258\/0956462011924218","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}